- Launched pivotal Phase 3 STEADFAST study with azeliragon in Alzheimer’s disease - Completed enrollment of AGATA Phase 2b study with liver-selective Glucokinase Activator in Type 2 diabetes, with expected data readout in mid-2016 - Initiated LOGRA Phase 2b study with oral GLP-1R agonist in Type 2
Data presented at Keystone Symposia on Molecular and Cellular Biology KEYSTONE, Colo. --(BUSINESS WIRE)--Feb. 22, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s
Oral Glucokinase Activator has potential to address an underlying cause of Type 2 diabetes Company expects to report topline results in mid-2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Feb. 9, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the
HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 28, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Stephen Holcombe , President
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential Topline results are expected at the end of 2016 HIGH POINT, N.C. --(BUSINESS WIRE)--Jan. 21, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development
Brings Decades of Pharmaceutical Research and Management Experience, Including Serving in Senior Roles at Pfizer and Eli Lilly Company HIGH POINT, N.C. --(BUSINESS WIRE)--Dec. 2, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT) today announced that Larry Altstiel has joined the company as Chief Medical
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 24, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, announced that Stephen Holcombe , President
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 13, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today announced that Stephen Holcombe ,
HIGH POINT, N.C. --(BUSINESS WIRE)--Nov. 12, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease (AD) and diabetes, today reported financial results for the
HIGH POINT, N.C. --(BUSINESS WIRE)--Oct. 22, 2015-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that Dr.